Understand the source comparison
Best Peptides for Belly Fat: Mechanism Comparison
CJC-1295/Ipamorelin GH secretagogue. Increases lipolysis via HSL activation Moderate (visceral adipocytes express 40% more GH receptors than subcutaneous) Weekly (CJC) + daily (Ipamorelin) 12.3% visceral fat reduction at 24 weeks in GH-deficient cohorts Survod
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- CJC-1295/Ipamorelin
- GH secretagogue. Increases lipolysis via HSL activation
- Moderate (visceral adipocytes express 40% more GH receptors than subcutaneous)
- Weekly (CJC) + daily (Ipamorelin)
- 12.3% visceral fat reduction at 24 weeks in GH-deficient cohorts
- Survodutide (GLP-1/GIP)
- Dual incretin agonist. Delays gastric emptying, suppresses appetite centrally
- High (caloric deficit preferentially mobilizes metabolically active visceral stores)
- Weekly
- 14.7% total body weight loss, 60% of fat loss from visceral depots
- Tesofensine
- Triple monoamine reuptake inhibitor. Increases thermogenesis and reduces hedonic intake
- High (beta-3 receptor activation + reduced hedonic eating)
- Daily
- 12.8% weight loss at 24 weeks, 2:1 visceral-to-subcutaneous fat loss ratio
- Hexarelin
- Selective GHSR-1a agonist. Acute GH pulses
- Moderate
- 2–3x daily
- Acute lipolysis within 60–90 minutes post-administration in fasted states
- Mazdutide
- GLP-1/glucagon dual agonist
- High (glucagon component enhances hepatic fat oxidation)
- Phase 2 data: 10.4% weight loss at 24 weeks, with preferential visceral reduction